WINDTREE THERAPEUTICS INC /DE/

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

751,872,888 shares

Common Stock · Exchange OTCID · Ticker WINT

2025-11-21 · 0001437749-25-035907

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

751,872,888 shares · Gross proceeds $50,000,000

Common Stock · Exchange OTC · Ticker WINT · Selling stockholders only · Use of proceeds General corporate purposes

2025-11-13 · 0001437749-25-034620

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

120,000,000 shares

Common Stock · Exchange NMS · Ticker WIND · Over-allotment 5,500 · Use of proceeds Proceeds will be used for general corporate purposes · Underwriters Thunderdome

2025-10-24 · 0001437749-25-031723

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2025-07-11 · 9999999995-25-002228

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

62,600,618 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Selling stockholders only · Use of proceeds Proceeds go to selling stockholders; no issuer proceeds

2025-07-10 · 0001437749-25-022494

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

42,168,035 shares

of the securities offered by this prospectus and we do not know when or in what amount the selling stockholders may sell their share · Exchange Nasdaq · Ticker WINT · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

2025-07-07 · 0001437749-25-022268

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

42,168,035 shares · Gross proceeds $0.00

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

2025-05-16 · 0001437749-25-017415

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2025-04-25 · 0001437749-25-013133

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2025-04-25 · 9999999995-25-001251

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

2025-04-24 · 0001437749-25-012981

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

31,247,383 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Subject Warrants exercisable for common stock · Selling stockholders only · Use of proceeds To receive proceeds from warrant exercises and ELOC share sales

2025-04-23 · 0001437749-25-012717

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

Range $2.90 to $6.80 · 5,000,000 shares · Gross proceeds $38,610

Common Stock · Ticker WINT · Over-allotment 0 · Warrants issued in prior financings · Use of proceeds working capital and other general corporate purposes · Flags self_underwritten, warrants · Underwriters self-underwritten

2025-02-14 · 0001437749-25-004006

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

10,679,758 shares · Gross proceeds $27,243,504

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Use of proceeds to pay expenses related to the issuance of the shares · Underwriters Seven Knots, LLC

2024-10-28 · 0001437749-24-032315

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

Price $3.31 · 10,679,758 shares · Gross proceeds $35,000,000

Common Stock · Exchange Nasdaq · Ticker WINT · Selling stockholders only · Use of proceeds for general corporate purposes · Underwriters Seven Knots, LLC

2024-09-03 · 0001437749-24-028217

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

27,668,106 shares

Common Stock · Exchange Nasdaq · Ticker WINT · Warrants issued in connection with prior private placements · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, to the company

2024-09-03 · 0001437749-24-028218

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2024-09-03 · 9999999995-24-002708

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2024-09-03 · 9999999995-24-002711

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows RW in the pre-IPO sequence.

10,679,758 shares · Gross proceeds $35,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Selling stockholders only · Use of proceeds No issuer proceeds; proceeds go to the Selling Stockholder · Underwriters Seven Knots, LLC

2024-08-23 · 0001437749-24-027669

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows S-1 and ends the active registration process.

2024-07-25 · 0001437749-24-023470

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Common Warrants and Pre-Funded Warrants · Flags warrants

2024-05-09 · 0001437749-24-015467

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2024-04-19 · 9999999995-24-001045

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $1,297,312

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Use of proceeds for general corporate purposes · Underwriters Ladenburg Thalmann & Co. Inc.

2024-01-16 · 0001437749-24-001388

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $2,054,024

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Use of proceeds For general corporate purposes. · Underwriters Ladenburg Thalmann & Co. Inc.

2023-11-09 · 0001437749-23-031257

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

2023-05-30 · 9999999995-23-001571

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $2.93 · 3,686,006 shares · Gross proceeds $10,799,998

Common Stock · Exchange Nasdaq · Ticker WINT · Over-allotment 552,900 · Each unit consists of one share of common stock and one common warrant · Common warrants exercisable at $2.93 per share, immediately exercisable, 5-year term · Flags units, warrants · Underwriters Ladenburg Thalmann

2023-04-21 · 0001437749-23-010764

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

2,008,928 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Over-allotment 301,339 · Common warrants exercisable at $ per share, expiring in 5 years; pre-funded warrants issued to limit ownership concentration · Use of proceeds for general corporate purposes · Flags warrants · Underwriters Ladenburg Thalmann

2023-04-19 · 0001437749-23-010602

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2023-04-19 · 9999999995-23-000981

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

2,008,928 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Over-allotment 301,339 · Common warrants and pre-funded warrants to purchase common stock · Flags warrants · Underwriters Ladenburg Thalmann

2023-04-13 · 0001437749-23-010198

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

2023-04-13 · 0001437749-23-010199

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

1,948,051 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · Over-allotment 292,207 · Common warrants and pre-funded warrants to purchase common stock · Flags warrants · Underwriters Ladenburg Thalmann

2023-04-07 · 0001437749-23-009711

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

2,758,620 shares · Gross proceeds $38,924

Common Stock and Warrants · Exchange Nasdaq Capital Market · Ticker WINT · Each Unit consists of one share of Common Stock and a Warrant to purchase one share of Common Stock · Warrants to purchase up to 275,862 shares of Common Stock at an amended exercise price of $0.1411 per share · Use of proceeds to receive gross proceeds from the exercise of warrants · Flags units, warrants, self_underwritten

2023-02-22 · 0001437749-23-004198

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

common stock and accompanying common warrants · Exchange Nasdaq Capital Market · Ticker WINT · Warrants exercisable immediately, expiring in 5 years · Underwriters Ladenburg Thalmann

2023-02-14 · 0001437749-23-003396

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

9,230,500 shares · Gross proceeds $890,013

Common Stock · Exchange Nasdaq · Ticker WINT · Warrants to purchase up to 9,230,500 shares of Common Stock with amended exercise price of $0.20 per share · Use of proceeds General corporate purposes

2023-01-20 · 0001437749-23-001437

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2,758,620 shares

Unit consisting of One Share of Common Stock and A Warrant to Purchase One Share of Common Stock · Exchange Nasdaq Capital Market · Ticker WINT · One Share of Common Stock and A Warrant to Purchase One Share of Common Stock · Warrants to purchase up to 279,889 shares of Common Stock amended to exercise price of $0.20 per share

2023-01-20 · 0001437749-23-001438

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2022-01-03 · 9999999995-22-000040

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $3.25 · 9,230,500 shares · Gross proceeds $29,999,125

Shares of Common Stock · Exchange NASDAQ · Ticker WINT · Warrants to purchase up to 9,230,500 shares of common stock, each with an exercise price of $3.60, exercisable immediately, expiring in 5 years · Flags warrants · Underwriters Oppenheimer & Co., Ladenburg Thalmann, National Securities Corporation

2021-03-24 · 0001437749-21-007041

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock and Warrants · Exchange Nasdaq Capital Market · Ticker WINT · Common Stock and Warrants · Warrants to purchase one share of common stock, exercisable immediately, expiring on the anniversary of issuance · Flags units, warrants · Underwriters Oppenheimer & Co., Ladenburg Thalmann, National Securities Corporation

2021-03-22 · 0001437749-21-006763

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

2020-09-29 · 9999999995-20-002616

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $7.25 · 2,758,620 shares · Gross proceeds $19,999,995

share of our common stock at an exercise price per share · Exchange Nasdaq · Ticker WINT · Over-allotment 413,793 · One Share of Common Stock and A Warrant to Purchase One Share of Common Stock · Warrants to purchase one share of common stock at $7.975, exercisable upon issuance, expiring in five years · Use of proceeds Proceeds to the company for general corporate purposes · Flags units, warrants · Underwriters Ladenburg Thalmann, National Securities Corporation

2020-05-21 · 0001437749-20-011490

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Price $9.55 · 2,094,240 shares · Gross proceeds $48,300,000

Common Stock · Exchange Nasdaq · Ticker WINT · Over-allotment 314,136 · One Share of Common Stock and A Warrant to Purchase One Share of Common Stock · Warrants to purchase common stock at 110% of the public offering price, exercisable for 5 years · Use of proceeds For general corporate purposes, including working capital and research and development · Flags units, warrants

2020-05-19 · 0001437749-20-011216

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

Follows S-1/A in the pre-IPO sequence.

2020-05-19 · 0001354457-20-000197

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows CERT and marks the registration effective.

2020-05-19 · 9999999995-20-001197

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows S-1/A and registers the class of securities for exchange listing.

2020-05-15 · 0001437749-20-010889

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $9.55 · 523,560 shares · Gross proceeds $9,200,000

Common Stock · Exchange OTCQB · Ticker WINT · Over-allotment 78,534 · Each unit consists of one share of common stock and a warrant to purchase 0.5 shares of common stock · Warrants exercisable at 120% of the public offering price, expiring 5 years after issuance

2020-05-14 · 0001437749-20-010653

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior EFFECT filing.

Price $9.79 · 510,725 shares · Gross proceeds $9,200,000

Common Stock · Exchange OTCQB · Ticker WINTD · Over-allotment 76,609 · Each unit includes one share of common stock and a warrant to purchase 0.5 shares of common stock · Warrants exercisable at 120% of the public offering price, expiring 5 years after issuance · Use of proceeds working capital, research and development, and other general corporate purposes · Flags units, warrants

2020-05-06 · 0001437749-20-009626

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2020-01-29 · 9999999995-20-000187

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1 in the pre-IPO sequence.

Common Stock and Warrants · Exchange Nasdaq · Ticker WINT · One Share of Common Stock and a Warrant to Purchase a Share of Common Stock · Warrants to purchase common stock at an exercise price of $ per share · Underwriters Ladenburg Thalmann

2020-01-27 · 0001437749-20-001187

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $3.87 · 13,221,430 shares · Gross proceeds $0.00

Common Stock, $0.001 par value per share · Exchange OTCQB · Ticker WINT · Warrants with $4.03 exercise price · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any

2020-01-21 · 0001437749-20-000849

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2019-05-15 · 9999999995-19-001128

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $4.16 · 37,308,973 shares

Common Stock · Exchange OTCQB · Ticker WINT · Includes warrants with exercise prices ranging from $3.68 to $6.50 · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, will be used for general corporate purposes · Flags warrants

2019-04-30 · 0001437749-19-008327

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2017-04-14 · 9999999995-17-000843

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Price $1.11 · 14,098,000 shares

Common Stock · Exchange Nasdaq · Ticker WINT · Warrants exercisable at $1.37 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any

2017-04-05 · 0001437749-17-006152

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $10,530,190

Common Stock · Exchange NASDAQ · Ticker WINT · Use of proceeds general corporate purposes · Underwriters Stifel, Nicolaus & Company, Incorporated

2016-05-24 · 0001140361-16-066869

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

Price $0.60 · 16,333,333 shares · Gross proceeds $34,999,999

share of our common stock and of one Series A warrant to purchase one share · Exchange NASDAQ · Ticker DSCO · Over-allotment 8,749,999 · Each Unit consists of one share of Common Stock and one Warrant (Series A) or one Pre-Funded Warrant and one Warrant (Series B) · Warrants exercisable at $0.70 (Series A) and $0.70 (Series B) per share, exercisable 7 years from issuance · Flags units, warrants · Underwriters Stifel, H.C. Wainwright & Co., LifeSci Capital

2015-07-21 · 0001140361-15-028098

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows 424B5 and supplements the active offering with updated prospectus details.

common · Each Series A unit includes 1 share of common stock and 1 Series A warrant; each Series B unit includes 2 warrants · Warrants to purchase common stock with exercise prices not specified in filing · Use of proceeds Proceeds from warrant exercises to be used for general corporate purposes · Flags warrants, units · Underwriters Stifel, Nicolaus & Company, Incorporated, H.C. Wainwright & Co., LLC, LifeSci Capital LLC

2015-07-17 · 0001140361-15-027846

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

share of our common stock and of one Series A warrant to purchase one share · Exchange NASDAQ Capital Market · Ticker DSCO · Series A Unit: 1 Common Stock + 1 Series A Warrant; Series B Unit: 1 Pre-Funded Series B Warrant + 1 Series B Warrant · Warrants exercisable at initial exercise price of $X per share, exercisable on or after issuance until 7th anniversary · Use of proceeds Proceeds to be used for debt repayment and working capital, with some proceeds potentially used for interest reduction agreements · Flags units, warrants · Underwriters Stifel, HC Wainwright & Co., LifeSci Capital

2015-07-16 · 0001140361-15-027732

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2014-06-13 · 9999999995-14-001774

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2014-02-12 · 9999999995-14-000430

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $2.00 · 25,000,000 shares · Gross proceeds $50,000,000

Common Stock · Exchange NASDAQ · Ticker DSCO · Over-allotment 3,750,000 · Use of proceeds general corporate purposes · Underwriters Stifel, Piper Jaffray, Lazard Capital Markets

2013-10-31 · 0001140361-13-040122

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Shares of Common Stock · Exchange NASDAQ Capital Market · Ticker DSCO · Underwriters Stifel, Piper Jaffray, Lazard Capital Markets

2013-10-30 · 0001140361-13-039974

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2013-06-20 · 9999999995-13-001862

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.50 · 9,500,000 shares · Gross proceeds $14,250,000

Shares of Common Stock · Exchange NASDAQ · Ticker DSCO · Over-allotment 1,425,000 · Use of proceeds Proceeds to us before expenses

2013-05-13 · 0001140361-13-020176

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

common stock · Exchange NASDAQ Capital Market · Ticker DSCO

2013-05-09 · 0001140361-13-019756

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $25,000,000

Common Stock, par value $0.001 per share · Exchange Nasdaq Capital Market · Ticker DSCO · Underwriters Stifel, Nicolaus & Company, Incorporated

2013-02-13 · 0001140361-13-006468

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $2.80 · 16,071,429 shares · Gross proceeds $45,000,000

Common · Exchange Nasdaq Capital Market · Ticker DSCO · Over-allotment 2,410,714 · Use of proceeds working capital · Underwriters Lazard Capital Markets, Stifel Nicolaus Weisel, Roth Capital Partners, LLC

2012-03-19 · 0001140361-12-016333

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker DSCO · Underwriters LAZARD CAPITAL MARKETS, STIFEL NICOLAUS WEISEL, ROTH CAPITAL PARTNERS, LLC

2012-03-15 · 0001140361-12-015898

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Gross proceeds $15,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker DSCO · Use of proceeds Working capital · Underwriters Lazard Capital Markets LLC

The current 424B5 filing by Discovery Laboratories (not Windtree Therapeutics) outlines an at-the-market equity program allowing the sale of up to $15 million in common stock via Lazard Capital Markets LLC (LCM) as the exclusive sales agent. This replaces the previous 424B3 filing, which detailed a specific draw down under a Common Stock Purchase Agreement with Kingsbridge Capital Limited. The new program permits sales over two years at the company's discretion, with LCM acting as an underwriter and receiving a 3% commission.

2011-12-15 · 0001140361-11-057548

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

34,906 shares · Gross proceeds $68,636

Common Stock of Windtree Therapeutics Inc. · Underwriters Kingsbridge Capital Limited

The prospectus supplement updates the June 2011 prospectus to reflect a draw down under the Common Stock Purchase Agreement with Kingsbridge Capital Limited, resulting in the issuance of 34,906 shares of common stock for $68,636, netting $67,366. This supplement amends the S-3 registration statement to include details of the September 2011 draw down and related securities offering.

2011-10-12 · 0001140361-11-049198

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

Discovery Laboratories Inc. is offering 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares in a unit offering. Each unit includes one share, a five-year warrant, and a fifteen-month warrant, sold at $2.35 per unit. The offering is underwritten by Lazard Capital Markets, with co-managers Boenning & Scattergood and Global Hunter Securities. The filing confirms the effectiveness of the registration statement.

2011-06-21 · 9999999995-11-001921

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $2.35 · 10,000,000 shares · Gross proceeds $21,855,000

Common · Exchange Nasdaq Capital Market · Ticker DSCO · 1 share of common stock, 1 Series I warrant (0.5 shares at $3.20) and 1 Series II warrant (0.5 shares at $2.94) per unit · Series I warrants to purchase 5,000,000 shares at $3.20 and Series II warrants to purchase 5,000,000 shares at $2.94 · Use of proceeds working capital and other general corporate purposes · Flags units, warrants · Underwriters Lazard Capital Markets, Boenning & Scattergood, Inc., Global Hunter Securities

Windtree Therapeutics Inc. is offering 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares in a registered offering. The offering includes units with one share of common stock, two warrants (5-year and 15-month), priced at $2.35 per unit. The company, a biotechnology firm focused on surfactant therapies for respiratory disorders, recently completed a 1-for-15 reverse stock split and faces regulatory and manufacturing challenges related to its lead product, Surfaxin®. The offering follows updated financial disclosures and FDA interactions regarding Surfaxin's approval process.

2011-02-17 · 0001144204-11-009463

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Shares of Common Stock · Exchange Nasdaq Capital Market · Ticker DSCO · Each unit consists of one share of common stock, a five-year warrant to purchase a share of common stock, and a fifteen-month warrant to purchase a share of common stock · Series I and Series II warrants to purchase common stock · Underwriters Lazard Capital Markets, Boenning & Scattergood, Inc., Global Hunter Securities

Windtree Therapeutics Inc. is offering an aggregate of shares of common stock and warrants to purchase shares of common stock in a shelf registration. The offering includes units consisting of common stock, five-year warrants, and fifteen-month warrants, with a public offering price per unit. The filing supplements a prospectus dated June 11, 2010, and includes details on underwriters, risk factors, and use of proceeds. The company is a biotechnology firm developing surfactant therapies for respiratory disorders.

2011-02-15 · 0001144204-11-009083

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

314,179 shares · Gross proceeds $991,275

Common Stock · Underwriters Kingsbridge Capital Limited

The current 424B3 filing by Windtree Therapeutics Inc. supplements the 2010 prospectus to reflect a draw down of $2,021,700 under a Common Stock Purchase Agreement with Kingsbridge Capital Limited. This resulted in the issuance of 314,179 shares of common stock, generating net proceeds of $972,937. The filing is part of an ongoing offering registered under the Securities Act of 1933.

2011-01-27 · 0001144204-11-004418

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Price $0.21 · 2,380,952 shares · Gross proceeds $500,000

Common Stock and Warrants · Exchange Nasdaq Capital Market · Ticker DSCO · One share of common stock and one warrant to purchase one-half of a share · Warrants to purchase 1,190,476 shares of common stock at $0.273 per share, exercisable for five years · Use of proceeds To support research and development activities of two drug product candidates

Windtree Therapeutics Inc. is offering 2,380,952 shares of common stock and warrants to purchase 1,190,476 shares directly to PharmaBio Development Inc. The offering consists of units priced at $0.21 per unit, with proceeds of approximately $500,000. The warrants are exercisable at $0.273 per share and may be redeemed by the company under specific conditions. The filing updates the prospectus to reflect this private placement, which differs from the previous 424B3 filing involving a draw down under a separate agreement with Kingsbridge Capital.

2010-10-13 · 0001144204-10-053597

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

Price $0.18 · 5,272,361 shares · Gross proceeds $972,657

Common Stock · Underwriters Kingsbridge Capital Limited

This prospectus supplement updates the June 11, 2010, prospectus for Windtree Therapeutics Inc. to reflect a draw down under the Common Stock Purchase Agreement with Kingsbridge Capital Limited. The company issued 5,272,361 shares of common stock to Kingsbridge for $972,657, resulting in net proceeds of $954,663 after fees. The draw down occurred during a pricing period starting September 22, 2010, with settlement dates on September 28 and October 4, 2010.

2010-10-05 · 0001144204-10-052467

WINDTREE THERAPEUTICS INC /DE/

Filing Timeline

10 comparable deals

Recent News